Drug
Lyl273
Lyl273: highest development phase Phase 1/2, developed by Lyell Immunopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Lyell Immunopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| LYL273 NCT05319314 | Phase 1/2 | Colorectal Cancer |
Latest
No recent events.
Follow Lyl273 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.